ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer


The study is aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer. The device is an experimental, portable, battery-operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

Study Arms

Experimental: NovoTTF-100L(O)

Patients receive TTFields using the NovoTTF-100L(O) System together with weekly Paclitaxel


  • Device: NovoTTF-100L(O)
  • Drug: Paclitaxel

Active Comparator: Best Standard of Care

Patients receive best standard of care with weekly Paclitaxel


  • Drug: Paclitaxel


  • 18 years of age and older
  • Epithelial histology of ovarian/primary peritoneal or fallopian tube carcinoma at the time of diagnosis
  • Life expectancy of ≥ 12 weeks
  • Maximum two prior lines of systemic therapy following diagnosis of platinum-resistance
  • Maximum total of 5 prior lines of systemic therapy
  • Amenable to receive weekly paclitaxel and able to operate the NovoTTF-100L(O) System
  • ECOG 0-1
  • Evaluable (measurable or non-measurable) disease in the abdominal/pelvic region per RECIST V1
  • Signed informed consent form for the study protocol